CRIS Current Research Information System

EVANGELISTI, CAMILLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.600
AS - Asia 4.659
EU - Europa 3.897
SA - Sud America 266
AF - Africa 248
OC - Oceania 6
Totale 14.676
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.548
SG - Singapore 1.265
CN - Cina 1.197
VN - Vietnam 1.187
GB - Regno Unito 872
IT - Italia 708
SE - Svezia 567
DE - Germania 524
HK - Hong Kong 323
FR - Francia 236
IN - India 222
RU - Federazione Russa 194
UA - Ucraina 187
BR - Brasile 170
IE - Irlanda 140
KR - Corea 104
FI - Finlandia 102
ZA - Sudafrica 100
JP - Giappone 77
NL - Olanda 73
EE - Estonia 71
JO - Giordania 51
CH - Svizzera 47
CI - Costa d'Avorio 47
TG - Togo 46
AR - Argentina 38
BG - Bulgaria 35
TH - Thailandia 31
AT - Austria 29
CA - Canada 29
PH - Filippine 28
BD - Bangladesh 26
ID - Indonesia 25
BE - Belgio 22
SC - Seychelles 22
PL - Polonia 17
EC - Ecuador 16
ES - Italia 16
MX - Messico 15
PK - Pakistan 14
TR - Turchia 14
IQ - Iraq 13
HR - Croazia 12
TW - Taiwan 12
CL - Cile 11
IR - Iran 11
LT - Lituania 11
SA - Arabia Saudita 11
UZ - Uzbekistan 10
PY - Paraguay 9
PT - Portogallo 8
VE - Venezuela 8
CO - Colombia 6
EG - Egitto 6
LB - Libano 6
AU - Australia 5
IL - Israele 5
MY - Malesia 5
NG - Nigeria 5
AL - Albania 4
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
MA - Marocco 4
NP - Nepal 4
PE - Perù 4
CR - Costa Rica 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
GR - Grecia 3
KH - Cambogia 3
AE - Emirati Arabi Uniti 2
BY - Bielorussia 2
DK - Danimarca 2
KE - Kenya 2
LA - Repubblica Popolare Democratica del Laos 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
SN - Senegal 2
TN - Tunisia 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
CG - Congo 1
CM - Camerun 1
GE - Georgia 1
GY - Guiana 1
JM - Giamaica 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
MU - Mauritius 1
MZ - Mozambico 1
NI - Nicaragua 1
Totale 14.671
Salva come PNG Salva come JPEG
Città #
Singapore 850
Southend 734
Ashburn 645
Fairfield 527
Chandler 357
Santa Clara 325
Hong Kong 305
Woodbridge 289
Houston 282
Ho Chi Minh City 276
San Jose 263
Wilmington 262
Bologna 225
Seattle 223
Hanoi 210
Ann Arbor 191
Hefei 190
Princeton 190
Cambridge 184
Dong Ket 159
Dallas 150
Beijing 141
Dublin 140
Boardman 121
Jacksonville 107
Nanjing 92
Lauterbourg 90
Los Angeles 87
Seoul 85
Helsinki 82
Westminster 79
Padova 77
Tokyo 63
Berlin 56
Council Bluffs 52
Amman 51
Abidjan 47
Lomé 46
Frankfurt am Main 45
New York 44
Jinan 43
Turin 41
San Diego 39
Changsha 38
Redmond 38
Saint Petersburg 38
Shenyang 38
Washington 38
Da Nang 35
Haiphong 35
Milan 35
Sofia 35
Bern 34
Bremen 34
Buffalo 31
Redondo Beach 30
Shanghai 30
Guangzhou 28
Johannesburg 28
Mülheim 28
São Paulo 26
Nanchang 24
Tianjin 24
Brussels 20
Des Moines 18
Falkenstein 18
Hebei 18
Hải Dương 18
London 18
Vienna 18
Munich 17
Norwalk 17
Bengaluru 16
Florence 16
Nuremberg 16
Rome 15
The Dalles 15
Chicago 14
Medford 14
Bangkok 13
Ninh Bình 13
Orem 13
Udine 13
Warsaw 13
Zhengzhou 13
Dearborn 12
Falls Church 12
Jakarta 12
Lappeenranta 12
Ningbo 12
Toronto 12
Haikou 11
Hangzhou 11
Jiaxing 11
Verona 11
Atlanta 10
Chengdu 10
Reggio Emilia 10
Taiyuan 10
Biên Hòa 9
Totale 9.623
Salva come PNG Salva come JPEG
Nome #
B-all complexity: Is targeted therapy still a valuable approach for pediatric patients? 302
Lamin A and prelamin A counteract invasiveness of osteosarcoma cells 269
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. 258
Combining prelamin A accumulation and oxidative stress: A strategy to target glioblastoma 252
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia. 221
Therapeutic targeting of CK2 in acute and chronic leukemias. 218
Improving nelarabine efficacy in T-cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. 208
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. 204
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 203
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 201
Phospholipases in Gliomas: Current Knowledge and Future Perspectives from Bench to Bedside 198
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. 198
The wide and growing range of lamin B‑related diseases: from laminopathies to cancer 194
Intranuclear 3'-phosphoinositide metabolism and Akt signaling: New mechanisms for tumorigenesis and protection against apoptosis? 192
Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. 191
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 191
Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. 189
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 188
Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulations of PC12 cells 183
Cutting edge: the role of mTOR signaling in laminopathies. 183
Emerging Roles of Phospholipase C Beta Isozymes as Potential Biomarkers in Cardiac Disorders 180
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 177
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 174
Pathobiology and therapeutic relevance of GSK-3 in chronic hematological malignancies. 173
Advances in Targeting Signal Transduction Pathways. 173
Targeting Wnt/beta-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. 173
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. 172
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 171
Nuclear protein kinase C 170
Nuclear inositol lipid metabolism: more than just second messenger generation? 170
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival er chaperone BIP/GRP78 and turning on the pro-apoptotic NF-κB. 170
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 169
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 168
GSK-3: a multifaceted player in acute leukemias. 166
Signaling Role of Pericytes in Vascular Health and Tissue Homeostasis 165
The involvement of signaling pathways in the pathogenesis of osteoarthritis: An update 164
Therapeutic targeting of polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblstic leukemia. 164
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 162
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 161
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. 160
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia 158
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. 158
Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. 156
The emerging multiple roles of nuclear Akt. 154
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. 154
Nuclear phosphoinositides and their roles in cell biology and disease. 153
Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. 151
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias 150
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 149
Nuclear diacylglycerol kinase-{zeta} is a negative regulator of cell cycle progression in C2C12 mouse myoblasts 147
The PI3K/Akt/mTOR Pathway 147
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. 145
Desmin and Plectin Recruitment to the Nucleus and Nuclei Orientation Are Lost in Emery-Dreifuss Muscular Dystrophy Myoblasts Subjected to Mechanical Stimulation 144
New advances in targeting aberrant signaling pathways in T-cell Acute Lymphoblastic Leukemia. 144
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 143
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells. 142
Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update. 140
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. 139
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance 136
TIS2/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest 136
Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts. 134
The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML) 134
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. 133
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. 132
GSK-3β: a key regulator of breast cancer drug resistance 131
Nuclear expression of diacylglycerol kinases: possible involvement in DNA replication. 129
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. 127
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance 126
Targeting the cancer initiating cell: the ultimate target for cancer therapy. 126
Intranuclear 3'-phosphoinositide metabolism and apoptosis protection in PC12 cells 124
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. 124
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. 123
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. 123
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. 122
Nuclear diacylglycerol kinases: emerging downstream regulators in cell signaling networks 121
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis. 119
PI3K isoforms inhibition associated with anti BCR-ABL1 drugs shows in vitro increased anti-leukemic activity in B-pre acute lymphoblastic leukemia. 118
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion 118
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. 117
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. 115
The role played by Wnt/beta-catenin signaling pathway in acute lymphoblastic leukemia. 115
New agents and approaches for targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell survival pathways. 114
DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. 114
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. 111
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy 105
Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance 101
Nuclear phosphoinositide specific phospholipase C (PI-PLC)-ss1: a central intermediary in nuclear lipid-dependent signal transduction 99
The unfolded protein response: a novel therapeutic target in acute leukemias. 99
Elevated tgf b2 serum levels in emery-dreifuss muscular dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 96
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. 94
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 94
INHIBITION OF CLASS I PHOSPHATIDYLINOSITOL 3-KINASES (PI3KS) ISOFORMS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL): WHICH IS THE BEST THERAPEUTIC STRATEGY? 93
Morphological and biochemical patterns in skeletal muscle apoptosis. 91
null 86
Defective collagen VI-NG2 axis impairs pericyte balance between proliferation and quiescence in COLVI-related myopathies 84
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 81
null 69
null 62
Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders 54
null 53
Totale 14.882
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.896
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021429 0 0 0 0 0 0 0 0 0 59 60 310
2021/20221.880 199 38 133 134 150 102 36 131 51 285 333 288
2022/20231.691 171 213 81 242 119 130 75 104 296 25 154 81
2023/2024614 36 67 74 50 94 173 18 22 18 29 21 12
2024/20251.967 42 175 162 150 491 133 131 76 23 88 94 402
2025/20264.629 398 597 515 351 575 298 485 169 915 326 0 0
Totale 14.965